The basis for disparate outcomes in clinical trials for COVID-19 medications.
In a groundbreaking study published in the open-access journal PLOS Medicine, a team of researchers from various institutions in Japan, including the University of Tokyo, the National Institute of Infectious Diseases, and others, have proposed a novel approach to enhance the efficiency of randomized clinical trials for COVID-19 drugs. The study, titled 'Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study combined with clinical data,' can be accessed at this URL.
The study, led by Dr. Shoya Iwanami, Dr. Shingo Iwami, Dr. Keisuke Ejima, and colleagues, suggests that enrolling participants as soon as possible after symptoms appear or setting enrolment criteria based on the time that has passed since symptom onset could significantly improve the outcomes of these trials.
The researchers used a model of SARS-CoV-2 dynamics to examine how viral load changes over time and found significant variation in the rate of decline between patients. This variation, they argue, could contribute to the inconsistent findings in clinical trials for antiviral COVID-19 drugs.
Interestingly, the study found that even if a drug reduced viral replication by 95%, a randomized clinical trial would need to enroll more than 13,000 people to detect statistically significant differences in viral load. However, when participants were treated within one day of onset of symptoms, only up to about 600 participants were needed for each group.
The study was funded by various grants from organizations such as Japan Society for the Promotion of Science (JSPS), Japan Agency for Medical Research and Development (AMED), Japan Science and Technology Agency (JST), and others. The authors declared that they have no competing interests.
Dr. Iwami suggests that the approach developed in the study could be applied to other types of drugs and different infectious diseases. The researchers are also planning to develop an online platform which supports designing clinical trials.
Future studies could employ more detailed models of SARS-CoV-2 dynamics to produce more reliable calculations of the numbers of participants needed for randomized clinical trials. This could pave the way for more efficient and effective drug trials in the fight against COVID-19.
Read also:
- Hospital's Enhancement of Outpatient Services Alleviates Emergency Department Strain
- Increased Chikungunya infections in UK travelers prompt mosquito bite caution
- Kazakhstan's Deputy Prime Minister holds discussions on the prevailing circumstances in Almaty
- In the state, Kaiser Permanente boasts the top-ranked health insurance program
